CQN-WA-SPIE
3.6.2021 18:21:06 CEST | Business Wire | Press release
In the bulleted section of the release dated June 2, 2021, all of the references to June should be July.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210602005138/en/
The updated release reads:
RIT AND SPIE PARTNER ON 2021 PHOTONICS FOR QUANTUM EVENT
The program, now in its third year, focuses on how photonic devices are impacting quantum science, technology, and applications
On 12-16 July, SPIE, the international society for optics and photonics, and Rochester Institute of Technology (RIT), will present the 2021 Photonics for Quantum Digital Forum . Previously an RIT initiative, this year marks a new iteration of this event in the form of a partnership between RIT and SPIE.
The five-day event will include more than 20 speakers from across international industry and research as well as an interactive poster session. Discussions and presentations will focus on quantum topics spanning applications, experiments, quantum photonic integrated circuits, materials, integration between dissimilar material systems, devices, and concepts to support a national quantum foundry.
Invited speakers include Qunnect’s Noel Goddard ; the US Air Force Research Laboratory’s Michael Fanto ; Imperial College London’s Ian A. Walmsley ; Eleni Diamanti of Sorbonne University’s Laboratoire d'Informatique de Paris 6; Laboratoire Matériaux et Phénomènes Quantiques’ Sara Ducci ; the University of Birmingham’s Kai Bongs ; and Anton Zeilinger of the University of Vienna and the Institute for Quantum Optics and Quantum Information of the Austrian Academy of sciences.
The Photonics for Quantum program sessions include:
- 12 July: Networks and Communication
- 13 July: Computing and Simulation
- 14 July: Sensing and Imaging
- 15 July: Components
- 16 July: Special events and panels, including Women in Quantum (in conjunction with the SPIE Women in Optics program), global government initiatives and funding, and workforce and education
“RIT is thrilled to partner with SPIE to present this year’s Photonics for Quantum conference,” said Don Figer , director of RIT’s Future Photon Initiative. “For the past two years, this event has provided an important forum to discuss the latest breakthroughs in quantum science and technology, as well as how to unlock this growing field’s potential. We look forward to expanding the conference by accessing SPIE’s worldwide network.”
“We’re very excited to be partnering with RIT on this growing event,” said SPIE Director of Industry Development Stephen Anderson . “It’s a wonderful opportunity to help showcase the fast-emerging field of quantum technology and the exciting possibilities that exist in it for photonics. With its particular focus on scientific and academic content, covering both fundamental research and in-lab developments, Photonics for Quantum is a terrific complement to the industry-focused SPIE Quantum West and a great addition to the SPIE calendar.”
Registration for Photonics for Quantum is now open. Visit our website for more information and to register for the event .
About RIT
Rochester Institute of Technology is home to leading creators, entrepreneurs, innovators, and researchers. Founded in 1829, RIT enrolls 18,600 students in more than 200 career-oriented and professional programs, making it among the largest private universities in the US. The university is internationally recognized and ranked for academic leadership in business, computing, engineering, imaging science, liberal arts, sustainability, and fine and applied arts. RIT also offers unparalleled support services for deaf and hard-of-hearing students . The cooperative education program is one of the oldest and largest in the nation. Global partnerships include campuses in China, Croatia, Dubai, and Kosovo.
About SPIE
SPIE is the international society for optics and photonics, an educational not-for-profit organization founded in 1955 to advance light-based science, engineering, and technology. The Society serves more than 258,000 constituents from 184 countries, offering conferences and their published proceedings, continuing education, books, journals, and the SPIE Digital Library. In 2020, SPIE provided over $5 million in community support including scholarships and awards, outreach and advocacy programs, travel grants, public policy, and educational resources. www.spie.org .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210602005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom